The Parexel Podcast | Episode 13: The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19
Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Chief Operating and Growth Officer, talks with Paul Bridges, Head of Consulting, and Sheela Hegde, a Partner with Parexel’s Health Advances subsidiary, about the regulatory, investing and clinical development changes that are most likely here to stay – The New Pragmatism. After listening, you can read more about Paul and Sheela’s perspective in this article: https://regulatory-access.parexel.com/parexels-covid-19-expert-content/covid-19-and-the-new-pragmatism
Related Insights
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
CTB Blog
FDA’s new biosimilar guidance explained: Key changes in reference product requirements
Mar 19, 2026
CTB Blog
Harmonizing UK and EU CTA submissions: Practical strategies from EU-CTR experience
Mar 19, 2026
CTB Blog
Decoding FDA's new ‘plausible mechanism framework’ guidance: what drug developers need to know
Feb 27, 2026
CTB Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
CTB Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
Related Insights
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
CTB Blog
FDA’s new biosimilar guidance explained: Key changes in reference product requirements
Mar 19, 2026
CTB Blog
Harmonizing UK and EU CTA submissions: Practical strategies from EU-CTR experience
Mar 19, 2026
CTB Blog
Decoding FDA's new ‘plausible mechanism framework’ guidance: what drug developers need to know
Feb 27, 2026
CTB Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
CTB Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025